![](/img/cover-not-exists.png)
PCN113 COST-MINIMISATION AND FIVE-YEAR BUDGET IMPACT ANALYSIS FOR MVASI® (BEVACIZUMAB BIOSIMILAR) IN ITALY
Despiégel, N., Cirillo, L., Gaikwad, I.Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.310
Date:
November, 2019
File:
PDF, 382 KB
2019